[HTML][HTML] Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia
TA Rousan, IT Aldoss, BD Cowley Jr… - American journal of …, 2010 - ncbi.nlm.nih.gov
Our patient, a 30-year-old man with end-stage renal disease attributed to congenital
dysplastic kidneys who had been on hemodialysis for 3.5 years, was admitted to the hospital …
dysplastic kidneys who had been on hemodialysis for 3.5 years, was admitted to the hospital …
[HTML][HTML] Mechanisms of piperacillin/tazobactam nephrotoxicity: piperacillin/tazobactam-induced direct tubular damage in mice
J Yang, YS Ko, HY Lee, Y Fang, SW Oh, MG Kim… - Antibiotics, 2023 - mdpi.com
Piperacillin/tazobactam (PT) is one of the most commonly prescribed antibiotics for critically
ill patients in intensive care. PT has been reported to cause direct nephrotoxicity; however …
ill patients in intensive care. PT has been reported to cause direct nephrotoxicity; however …
Evaluation of the use of piperacillin/tazobactam (Tazocin®) at Hamad General Hospital, Qatar: are there unjustified prescriptions?
FY Khan, A Elhiday, IF Khudair, H Yousef… - Infection and drug …, 2012 - Taylor & Francis
Objectives The aim of this study was to evaluate the appropriateness of piperacillin/
tazobactam (Tazocin®; Pfizer, New York, NY) usage in our hospital. Subjects and methods …
tazobactam (Tazocin®; Pfizer, New York, NY) usage in our hospital. Subjects and methods …
Efficiency of tazobactam/piperacillin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2-pneumoperitoneum
M Bette, RM Nüsing, R Mutters, ZB Zamora… - Shock, 2006 - journals.lww.com
Insufflation of ozonized oxygen into the peritoneum (O 3/O 2-pneumoperitoneum [O 3/O 2-
PP]) of rats reduced the lethality of peritonitis. We evaluated the prophylactic effect of O 3/O 2 …
PP]) of rats reduced the lethality of peritonitis. We evaluated the prophylactic effect of O 3/O 2 …
Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection
AA Erasmo, AC Crisostomo, LN Yan, YS Hong… - Asian journal of …, 2004 - Elsevier
OBJECTIVES: Treatment of intra-abdominal infections remains a challenge because of their
polymicrobial nature and associated mortality risk. Broad-spectrum empiric coverage is …
polymicrobial nature and associated mortality risk. Broad-spectrum empiric coverage is …
An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage
J Lv, G Wu, F Zhang, X Su - European Journal of Hospital Pharmacy, 2022 - ejhp.bmj.com
Piperacillin-tazobactam is a broad-spectrum antimicrobial agent that is commonly used in
clinical practice. The development of delayed drug hypersensitivity reaction (DHR) has been …
clinical practice. The development of delayed drug hypersensitivity reaction (DHR) has been …
Intravitreal piperacillin/tazobactam in the management of multidrug-resistantPseudomonas aeruginosaendophthalmitis
A Pathengay, A Mathai, GY Shah… - Journal of Cataract & …, 2010 - journals.lww.com
DISCUSSION Gram-negative bacilli such as P aeruginosa can rapidly develop β-lactamase-
mediated resistance to antibiotic agents. 1 Although amikacin and ceftazidime are the most …
mediated resistance to antibiotic agents. 1 Although amikacin and ceftazidime are the most …
哌拉西林/他唑巴坦治疗医院获得性肺炎的多中心临床研究
周新， 万欢英， 朱惠莉， 施毅， 林章树， 蒋捍东… - 中国呼吸与危重监护 …, 2009 - cqvip.com
目的评价哌拉西彬他唑巴坦(特治星) 治疗医院获得性肺炎的疗效与安全性. 方法采用多中心,
开放, 非对照方法治疗医院获得性肺炎, 给药方案为每次4.5 g 静脉注射, q8h, 7~ 14d. 结果共250 …
开放, 非对照方法治疗医院获得性肺炎, 给药方案为每次4.5 g 静脉注射, q8h, 7~ 14d. 结果共250 …
Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific …
N Murao, H Ohge, K Ikawa, Y Watadani… - International Journal of …, 2017 - Elsevier
Abstract Piperacillin-tazobactam (PIP-TAZ) is commonly used to treat intraabdominal
infections; however, its penetration into abdominal sites is unclear. A pharmacokinetic …
infections; however, its penetration into abdominal sites is unclear. A pharmacokinetic …
Concentrations of piperacillin–tazobactam in human jaw and hip bone
B Al-Nawas, M Kinzig-Schippers, F Soergel… - Journal of Cranio …, 2008 - Elsevier
OBJECTIVES: It is unclear to what extent pharmacokinetic data from bone outside the facial
area can be transferred to the maxillofacial area. The aim of this study was to evaluate the …
area can be transferred to the maxillofacial area. The aim of this study was to evaluate the …